In a preliminary study with 30 patients, we showed that thymidylate synthase (TYMS) and RAD23 homolog B (RAD-23B) expression in CTCs before and after NCRT could predict tumor response in LARC patients [18]. This evidence concerns the gene RAD23B and neoplasm.